Paige, an artificial intelligence-enabled system for high-speed, low-cost cancer diagnosis and treatment, has closed a $45 million Series B funding round, according to a Dec. 18 news release.
The startup was founded by researchers at Memorial Sloan Kettering Cancer Center with a primary goal of commercializing healthcare-improving technology developed at the New York City-based institution. The latest round of funding will be used to grow Paige's portfolio, support existing technologies through the FDA clearance process and expand commercial efforts around the world.
Paige's "digital pathology ecosystem" uses AI to deliver advanced computational diagnostics that improve the accuracy of cancer detection and diagnosis, offer lower-cost treatment recommendations and discover new biomarkers, cancer treatment pathways and drug efficacy information.
More articles on AI:
Physician viewpoint: AI use might lead to overdiagnosis of cancer
Brigham and Women's, Mass General test AI-driven patient safety platform
80% of healthcare professionals say AI has decreased burnout: 3 notes